Prometheus Biosciences, Inc. (RXDX)
| Market Cap | 1.85B |
| Revenue (ttm) | 6.29M |
| Net Income (ttm) | -108.32M |
| Shares Out | 39.20M |
| EPS (ttm) | -2.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 722,014 |
| Open | 49.17 |
| Previous Close | 49.50 |
| Day's Range | 45.51 - 49.44 |
| 52-Week Range | 21.12 - 51.96 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 54.99 (+16.8%) |
| Earnings Date | Aug 10, 2022 |
About RXDX
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IB... [Read more...]
Financial Performance
In 2021, RXDX's revenue was $3.13 million, an increase of 154.60% compared to the previous year's $1.23 million. Losses were -$90.20 million, 142.9% more than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for RXDX stock is "Buy." The 12-month stock price forecast is 54.99, which is an increase of 16.75% from the latest price.
News
Prometheus Biosciences, Inc. (RXDX) Reports Q2 Loss, Tops Revenue Estimates
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 81.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022 -
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022
- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 -
Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis
- G lobal Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies -
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn's disease patients -
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -5.13% and 459.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s...
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
- Advanced and expanded development of PRA023 across three immune-mediated indications -
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Di...
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways -
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Pr...
- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn's disease expected in fourth quarter 2022 -
Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, ...
Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, ...
Prometheus Biosciences Posts Phase 1 Data On Lead Therapeutic Candidate
Prometheus Biosciences Inc (NASDAQ: RXDX) has reported topline results from its Phase 1 trial of PRA023 in healthy volunteers. PRA023 was well-tolerated, with no safety signal identified during the study.
Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indication...
Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity
Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress
- Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 -
How to Use New Analyst Coverage to Find Strong Stocks to Buy
One way to find potential winning stocks is to search for companies that recently landed new analyst coverage.
Prometheus Biosciences to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, ...
Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Off...
Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress
- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) -
In Memoriam – Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed Away
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), with great sorrow announced today that its Chairman of the Board, Tadataka (Tachi) Yamada, M.D., KBE, passed awa...
Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Croh...
- First Anti-TL1A trial in Crohn's Disease -
Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Pla...
-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600-
Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, a...
3 Small Cap Stocks That Are Short Squeeze Candidates
Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.
Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference
SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, a...